I am very excited to announce a new feature for BiotechDueDiligence readers. Fellow biotech enthusiast Mike O'Neill (be sure to follow him on Twitter @MikeOinSATX) has graciously agreed to archive his biotech investor relations questions ("IRQs") and answers here on the website.
What are the "IRQs"? Mike starts his due diligence on any biotech stock by asking their IR department the same five questions.
Continue reading for a brief introduction to Mike's philosophy and the key topics about which he asks each and every biotech company on his watch list:
What are the "IRQs"? Mike starts his due diligence on any biotech stock by asking their IR department the same five questions.
Continue reading for a brief introduction to Mike's philosophy and the key topics about which he asks each and every biotech company on his watch list:
With so many biotechnology companies publicly traded on the market, finding the right company to trade or invest in can be very time consuming and frustrating. The questions that I have put together are just a snapshot, but they provide a valuable starting point.
When it comes to trading, most would agree that timing is everything. Whether you are a long term investor, swing or day trader, nobody wants to get caught holding shares of a company that announces a secondary offering (dilution). Likewise, a company that lacks catalysts will not generate much interest in the market. Ideally, we are all looking for a company that has sufficient financial resources to get past their next know catalyst or further.
Given the answers to the 5 questions that I have put together, one can quickly assess if the conditions are present that warrant further research.
I sincerely hope that you will find this to be an asset and I encourage you to join myself and Dr. Andrew Goodwin on Twitter to share your own research, knowledge and opinions regarding any of the companies found on this resource.
Navigate over to the "IR Questions" page for Mike's Five Questions and an index of responses from numerous biotech companies.
When it comes to trading, most would agree that timing is everything. Whether you are a long term investor, swing or day trader, nobody wants to get caught holding shares of a company that announces a secondary offering (dilution). Likewise, a company that lacks catalysts will not generate much interest in the market. Ideally, we are all looking for a company that has sufficient financial resources to get past their next know catalyst or further.
Given the answers to the 5 questions that I have put together, one can quickly assess if the conditions are present that warrant further research.
I sincerely hope that you will find this to be an asset and I encourage you to join myself and Dr. Andrew Goodwin on Twitter to share your own research, knowledge and opinions regarding any of the companies found on this resource.
Navigate over to the "IR Questions" page for Mike's Five Questions and an index of responses from numerous biotech companies.
RSS Feed
